HKSE:02096 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:02096 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the six months ended in Dec. 2024, Simcere Pharmaceutical Group paid HK$306 Mil more to buy back shares than it received from issuing new shares. It received HK$60 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0 Mil from paying cash dividends to shareholders. It spent HK$495 Mil on other financial activities. In all, Simcere Pharmaceutical Group spent HK$741 Mil on financial activities for the six months ended in Dec. 2024.
The historical data trend for Simcere Pharmaceutical Group's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 2,790.06 | -1,989.19 | -841.65 | -978.75 | -434.97 |
Simcere Pharmaceutical Group Semi-Annual Data | ||||||||||||||
Dec17 | Dec18 | Jun19 | Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | Dec24 | |
Cash Flow from Financing | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-513.95 | -529.79 | -448.96 | 308.47 | -740.90 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Simcere Pharmaceutical Group's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing | (A: Dec. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | -734.542 | + | -172.655 | + | 0 | + | -428.653 | + | 997.41 |
= | -338 |
Simcere Pharmaceutical Group's Cash from Financing for the quarter that ended in Dec. 2024 is:
Cash Flow from Financing | (Q: Dec. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | -305.616 | + | 60.141 | + | 0 | + | 0 | + | -495.421 |
= | -741 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-432 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (HKSE:02096) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Simcere Pharmaceutical Group's issuance of stock for the six months ended in Dec. 2024 was HK$0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Simcere Pharmaceutical Group's repurchase of stock for the six months ended in Dec. 2024 was HK$-306 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Simcere Pharmaceutical Group's net issuance of debt for the six months ended in Dec. 2024 was HK$60 Mil. Simcere Pharmaceutical Group received HK$60 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Simcere Pharmaceutical Group's net issuance of preferred for the six months ended in Dec. 2024 was HK$0 Mil. Simcere Pharmaceutical Group paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Simcere Pharmaceutical Group's cash flow for dividends for the six months ended in Dec. 2024 was HK$0 Mil. Simcere Pharmaceutical Group received HK$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Simcere Pharmaceutical Group's other financing for the six months ended in Dec. 2024 was HK$-495 Mil. Simcere Pharmaceutical Group spent HK$495 Mil on other financial activities.
Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Artking Global Limited | 2501 Other | |
Fortune Fountain Investment Limited | 2501 Other | |
Li Shimeng | 2501 Other | |
P&h Holdings Group Ltd. | 2501 Other | |
Peng Suqin | 2501 Other | |
Ren Weidong | 2501 Other | |
Ren Yong | 2501 Other | |
Ren Zhen | 2501 Other | |
Right Wealth Holdings Limited | 2501 Other | |
Simcere Holding Limited | 2501 Other | |
Wang Xi | 2501 Other | |
Simcere Pharmaceutical Holding Limited | 2501 Other | |
Ren Jinsheng | 2202 Interest of your spouse | |
Excel Investments Group Limited | 2501 Other | |
Simcere Investments Group Limited | 2501 Other |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.